NasdaqGS:REGNBiotechs
Is It Time To Reassess Regeneron (REGN) After Its Mixed Share Price Performance?
Wondering whether Regeneron Pharmaceuticals at around US$749 a share still offers value or is already pricing in its strengths? This breakdown focuses squarely on what you are paying for today.
The stock is up 1.7% over the last 7 days, has a 4.1% decline over 30 days, a 3.5% decline year to date, but is up 18.8% over 1 year, 8.7% lower over 3 years and 55.7% higher over 5 years. This gives a mixed picture of momentum and risk perception.
Recent coverage around Regeneron Pharmaceuticals has...